Video Review: Talking Biopolitics – A conversation with Paul Knoepfler and Nathaniel Comfort
By Dr. Rebecca Dimond,
BioNews
| 02. 01. 2016
Untitled Document
On 26 January 2016, the Center for Genetics and Society hosted an online discussion on 'Exploring heritable genetic modification: the promise and perils of altering future humans'. Paul Knoepfler, author of the 2015 book 'GMO Sapiens: The Life-Changing Science of Designer Babies', was interviewed by science historian Nathaniel Comfort.
I was looking forward to this webinar. The discussion was timely, following the passing of legislation on mitochondrial donation in the UK in 2015, and amid current debates about gene-editing technologies, such as CRISPR. Introducing the conversation, Marcy Darnovsky told the audience that genetic modification is 'now with us', a thought she described as both lively and sobering. Knoepfler's views about these developments are well known – during the UK mitochondrial donation debates, he contributed evidence to the scientific reviews, was mentioned at the House of Commons and House of Lords and hosts his own popular blog. He recently tweeted that he was 'excited about genetic modification' but was also cautious about 'talk of clinic use'.
Much of the conversation focused on the risks and benefits of...
Related Articles
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...
